Literature DB >> 22995588

A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma.

Gang Peng1, Tao Wang, Kun-Yu Yang, Sheng Zhang, Tao Zhang, Qin Li, Jun Han, Gang Wu.   

Abstract

BACKGROUND AND
PURPOSE: To compare clinical outcomes and toxicities of two-dimensional conventional radiation therapy (2D-CRT) and intensity modulated radiation therapy (IMRT) for the treatment of nasopharyngeal carcinoma (NPC).
MATERIALS AND METHODS: Between July 2003 and October 2008, 616 patients with non-metastatic stage I to IVb NPC were prospectively randomized to receive 2D-CRT (n=310; mean age, 44.8±13.6 years) or IMRT (n=306; mean age, 46.7±12.5 years). Clinical outcomes and acute and late toxicities were determined and compared.
RESULTS: The 2 groups were comparable with respect to all parameters of demographics and disease characteristics (all, p>0.05). Median follow-up was 42 months (range, 1-83 months). The 5-year actuarial local control rate was 90.5% in the IMRT group and 84.7% in the 2D-CRT group. The local control rates were 91% for stage T3 and 81.5% for stage T4 disease in the IMRT group and 80% and 62.2% in the 2D-CRT group, respectively. The 5-year actuarial nodal relapse-free survival (NRFS) rate was 92.4% in the IMRT and 92.9% in the 2D-CRT group (p>0.05). The NRFS was 93.9% for N2 disease in the IMRT group and 91.4% in the 2D-CRT group (p=0.02). The 5-year overall survival (OS) rate was 79.6% for the IMRT group and 67.1% for the 2D-CRT group (p=0.001). When stratified for stage, a significant difference was only noted for stage III disease. In terms of radiation-induced toxicities, patients in IMRT group had significantly lower radiation-induced toxicities than those in 2D-CRT group.
CONCLUSION: IMRT provides improved local-recurrence free survival, especially in late-stage NPC patients and is associated with a lower incidence of toxicities.
Copyright © 2012. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22995588     DOI: 10.1016/j.radonc.2012.08.013

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  220 in total

1.  Omitting the lower neck and sparing the glottic larynx in node-negative nasopharyngeal carcinoma was safe and feasible, and improved patient-reported voice outcomes.

Authors:  F Xiao; S Dou; Y Li; W Qian; F Liang; L Kong; X Wang; K Wu; C Hu; G Zhu
Journal:  Clin Transl Oncol       Date:  2018-12-04       Impact factor: 3.405

2.  Systemic chemotherapy followed by locoregional definitive intensity-modulated radiation therapy yields prolonged survival in nasopharyngeal carcinoma patients with distant metastasis at initial diagnosis.

Authors:  Shao-xuan Hu; Xiao-hui He; Mei Dong; Bo Jia; Sheng-yu Zhou; Jian-liang Yang; Sheng Yang; Chang-Gong Zhang; Peng Liu; Yan Qin; Lin Gui
Journal:  Med Oncol       Date:  2015-07-29       Impact factor: 3.064

3.  Hypothalamic-pituitary-thyroid dysfunction induced by intensity-modulated radiotherapy (IMRT) for adult patients with nasopharyngeal carcinoma.

Authors:  Shuang Huang; Xiaosheng Wang; Chaosu Hu; Hongmei Ying
Journal:  Med Oncol       Date:  2013-09-03       Impact factor: 3.064

4.  The potential of helical tomotherapy in the treatment of head and neck cancer.

Authors:  Dirk Van Gestel; Dirk Verellen; Lien Van De Voorde; Bie de Ost; Geert De Kerf; Olivier Vanderveken; Carl Van Laer; Danielle Van den Weyngaert; Jan B Vermorken; Vincent Gregoire
Journal:  Oncologist       Date:  2013-05-30

5.  Efficacy and Safety of Limited-Margin Conformal Radiation Therapy for Pediatric Rhabdomyosarcoma: Long-Term Results of a Phase 2 Study.

Authors:  Christopher L Tinkle; Alberto Pappo; Jianrong Wu; Shenghua Mao; Chia-Ho Hua; Barry L Shulkin; M Beth McCarville; Sue C Kaste; Andrew M Davidoff; Armita Bahrami; Daniel M Green; Kirsten K Ness; Thomas E Merchant; Sheri L Spunt; Matthew J Krasin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-01-25       Impact factor: 7.038

6.  A randomized phase III study between sequential versus simultaneous integrated boost intensity-modulated radiation therapy in nasopharyngeal carcinoma.

Authors:  Chawalit Lertbutsayanukul; Anussara Prayongrat; Danita Kannarunimit; Chakkapong Chakkabat; Buntipa Netsawang; Sarin Kitpanit
Journal:  Strahlenther Onkol       Date:  2018-01-04       Impact factor: 3.621

Review 7.  Does East meet West? Towards a unified vision of the management of Nasopharyngeal carcinoma.

Authors:  Elaine Johanna Limkin; Pierre Blanchard
Journal:  Br J Radiol       Date:  2019-05-31       Impact factor: 3.039

8.  Clinical observation and quality of life in terms of nasal sinusitis after radiotherapy for nasopharyngeal carcinoma: long-term results from different nasal irrigation techniques.

Authors:  H-H Luo; Z-C Fu; H-H Cheng; S-G Liao; D-S Li; L-P Cheng
Journal:  Br J Radiol       Date:  2014-05-12       Impact factor: 3.039

9.  Recurrent oropharyngeal cancer after organ preserving treatment: pattern of failure and survival.

Authors:  M de Ridder; Z A R Gouw; J J Sonke; A Navran; B Jasperse; J Heukelom; M E T Tesselaar; W M C Klop; M W M van den Brekel; Abrahim Al-Mamgani
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-12-09       Impact factor: 2.503

10.  Nasopharyngeal carcinoma with intracranial extension in the era of intensity-modulated radiotherapy: case-control study using propensity score matching method.

Authors:  Cai-Neng Cao; Jing-Wei Luo; Li Gao; Guo-Zhen Xu; Jun-Lin Yi; Xiao-Dong Huang; Su-Yan Li; Jian-Ping Xiao; Zhong Zhang
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-08-18       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.